Interstice Therapeutics
Pre-clinicalBiotech BioPharma company focused on rapid development and approval of novel 505b(2) drugs to address anticipated and/or real world branded New Drug Application (NDA) treatment adoption gaps.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $4M
About
Biotech BioPharma company focused on rapid development and approval of novel 505b(2) drugs to address anticipated and/or real world branded New Drug Application (NDA) treatment adoption gaps.
OphthalmologyDrug Delivery
Funding History
1Total raised:$4M
Seed$4MFeb 15, 2022